IMMUNEONCO-B(01541): The phase III clinical trial of IMM0306 for the treatment of recurrent/refractory follicular lymphoma has completed dosing for the first patient.

IMMUNEONCO-B(01541) announced that the Phase III clinical trial of IMM0306 in combination with rituximab for the treatment of relapsed/refractory follicular lymphoma has successfully completed dosing for the first patient. IMM0306, independently developed by the group, is a bispecific molecule targeting cluster of differentiation 47 (CD47) and cluster of differentiation 20 (CD20). It is the world's first CD47 and CD20 dual-targeting bispecific molecule to enter clinical stage. IMM0306 inhibits the CD47-SIRP interaction to block the "don't eat me" signal, enhances the interaction of Fc-FcRIIa and Fc-FcRIIIa to activate macrophages and NK cells, and preferentially binds to CD20 rather than CD47 to effectively eliminate malignant B cells while minimizing toxicity, thereby improving treatment outcomes. As of the date of this announcement, the group holds global intellectual property and commercialization rights for IMM0306.